anti-HER2 ADC (Pfizer)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug Nameanti-HER2 ADC (Pfizer)

Drug Alias NameNG-HER2 ADCAnti-NG-HER2 ADCPF-06804103

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Aur0101 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionImmunomodulatorsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsTriple Negative Breast NeoplasmsBreast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesRussian FederationItaly +[7]

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesFudan University

Inactive CompaniesPfizer Inc

Active IndicationsTriple Negative Breast NeoplasmsBreast Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A